 -- Received FDA approval of IMCIVREETM setmelanotide, the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency -- -- Announced positive topline data from Phase 3 pivotal trial evaluating setmelanotide in Bardet-Biedl and Alström syndromes; on-track to complete regulatory submissions to FDA and EMA for BBS in 2H 2021 -- 